Abstract:Background: The aggregation and spread of misfolded amyloid structured proteins, such as tau and α-synuclein, are key pathological features associated with neurodegenerative disorders, including Alzheimer's and Parkinson's disease. These proteins possess a prion-like property, enabling their transmission from cell to cell leading to propagation throughout the central and peripheral nervous systems. While the mechanisms underlying their intracellular spread are still being elucidated, targeting the extracellular space has emerged as a potential therapeutic approach. The glymphatic system, a brain-wide pathway responsible for clearing extracellular metabolic waste from the central nervous system, has gained attention as a promising target for removing these toxic proteins. Methods: In this study, we investigated the impact of long-term modulation of glymphatic function on tau aggregation and spread by chronically treating a mouse model of tau propagation with a pharmacological inhibitor of AQP4, TGN-020. Thy1-hTau.P301S mice were intracerebrally inoculated with tau into the hippocampus and overlying cortex, and subsequently treated with TGN-020 (3 doses/week, 50 mg/kg TGN-020, i.p.) for 10-weeks. During this time, animal memory was studied using cognitive behavioural tasks, and structural MR images were acquired of the brain in vivo prior to brain extraction for immunohistochemical characterisation. Results: Our findings demonstrate increased tau aggregation in the brain and transhemispheric propagation in the hippocampus following the inhibition of glymphatic clearance. Moreover, disruption of the glymphatic system aggravated recognition memory in tau inoculated mice and exacerbated regional changes in brain volume detected in the model. When initiation of drug treatment was delayed for several weeks post-inoculation, the alterations were attenuated. Conclusions: These results indicate that by modulating AQP4 function and, consequently, glymphatic clearance, it is possible to modify the propagation and pathological impact of tau in the brain, particularly during the initial stages of the disease. These findings highlight the critical role of the glymphatic system in preserving healthy brain homeostasis and offer valuable insights into the therapeutic implications of targeting this system for managing neurodegenerative diseases characterized by protein aggregation and spread.

Methylene blue accelerates liquid-to-gel transition of tau condensates impacting tau function and pathology

Myricetin slows liquid–liquid phase separation of Tau and activates ATG5-dependent autophagy to suppress Tau toxicity

Tau protein liquid–liquid phase separation can initiate tau aggregation

Liquid − liquid phase separation of tau: Driving forces, regulation, and biological implications

Glymphatic inhibition exacerbates tau propagation in an Alzheimer's disease model

Conformational Expansion of Tau in Condensates Promotes Irreversible Aggregation.

Liquid-liquid phase separation induces pathogenic tau conformations in vitro

Visualization of soluble tau oligomers in TauP301L-BiFC transgenic mice demonstrates the progression of tauopathy

Tau liquid–liquid phase separation: At the crossroads of tau physiology and tauopathy

Tannic acid as a biphasic modulator of tau protein liquid-liquid phase separation

Customized Intranasal Hydrogel Delivering Methylene Blue Ameliorates Cognitive Dysfunction Against Alzheimer's Disease.

Effect of Natural Osmolytes on Recombinant Tau Monomer: Propensity of Oligomerization and Aggregation

Atomic insights into the inhibition of R3 domain of tau protein by epigallocatechin gallate, quercetin and gallic acid

Cyclic dipeptide-based small molecules modulate zinc-mediated liquid-liquid phase separation of tau

Liquid-liquid phase separation of tau driven by hydrophobic interaction facilitates fibrillization of tau

Liquid–liquid phase separation in Alzheimer's disease

Myricetin Inhibits -Synuclein Amyloid Aggregation by Delaying the Liquid-to-Solid Phase Transition

Dynamic-Inspired Perspective on the Molecular Inhibitor of Tau Aggregation by Glucose Gallates Based on Human Neurons

Rescue of synaptosomal glutamate release defects in tau transgenic mice by the tau aggregation inhibitor hydromethylthionine

Liquid–liquid phase separation of tau: From molecular biophysics to physiology and disease

Methylene Blue Inhibits Caspases by Oxidation of the Catalytic Cysteine